Réf :HematoStat.net ; 2 (3) : V49   Current treatment strategies and emerging therapies for cutaneous lymphoma DOI: 10.1111/1346-8138.16289

Réf :HematoStat.net ; 2 (3) : V48   Prognostic value of circulating tumor DNA in lymphoma: a meta-analysis DOI: 10.1007/s10238-021-00718-8

Réf :HematoStat.net ; 2 (3) : V47   Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients DOI: 10.1182/blood.2021013445

Réf :HematoStat.net ; 2 (3) : V46   Circulating Tumor DNA in Lymphoma: Principles and Future Directions doi: 10.1158/2643-3230.BCD-21-0029

Réf :HematoStat.net ; 2 (3) : V45   Polatuzumab Vedotin in Précédently Untreated Diffuse Large B-Cell Lymphoma DOI: 10.1056/NEJMoa2115304

Réf :HematoStat.net ; 2 (3) : V44   Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.  https://doi.org/10.1016/ S1470-2045(21)00139-X